Abstract
Since the introduction of zidovudine 18 years ago, the treatment of HIV has been rapidly evolving. Current therapies target the HIV retrovirus successfully but contain their own perils. Active therapies with reduced adverse effects and long-term activity in the presence of, or reduced susceptibility to, antiviral resistance continue to be needed. Furthermore, more convenient agents that may facilitate adherence to therapy are a goal of new drug development. This review addresses these clinical needs, with a discussion of several new drugs currently in the clinical trial pipeline.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
